Cell Culture Media Market To Witness Massive Growth By 2030

Cell Culture Media Industry

The global cell culture media market size was estimated at USD 4.73 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 12.54% from 2024 to 2030. Cell culture media is generally a gel or liquid including compounds required to regulate and support the growth of cells or microorganisms used in the manufacturing of biopharmaceuticals. Culture media is a critical ingredient in biopharmaceutical manufacturing, aiding the growth of cells, and is the fastest-growing segment within this market. This growth is mainly driven by growing demand for biopharmaceuticals, favorable governmental policies, and increasing investment in R&D.

The outbreak of COVID-19 has improved demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, Vero cell line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium manufactured by Lonza Bioscience is a protein-free medium, of non-animal origin designed to support the growth of Vero cells and MDCK.

Furthermore, cell culture-produced AAV vectors have also gained thrust as one of the most effective protein and gene delivery tools in vaccine manufacturing as well as gene therapy. Key market players are expanding their production capabilities. In 2021, Sartorius increased its production in all regions due to elevated demand in its core business and to additional customer needs related to COVID-19 therapeutics and COVID-19 vaccines. The biosimilars market is on the cusp of momentous growth. This growth is due to several mAb biosimilars that are anticipated to be launched in a few years as patents on significant drugs, such as trastuzumab (Herceptin from Roche), infliximab (Remicade from J&J), and Adalimumab (Humira from Abbott) are going to expire.

Gather more insights about the market drivers, restrains and growth of the Global Cell Culture Media Market

Cell Culture Media Market Segments Highlights:

By product, the serum-free media (SFM) segment held the highest market share of 36.0% in 2023. The use of serum-free media signifies a significant tool, which allows the researchers to perform specific applications or grow a specific cell type without using serum.
The biopharmaceutical production segment dominated the market with a revenue share of 42.71% in 2023. Strategic activities by key biopharmaceutical companies, increasing R&D, demand for more reproducible and better-defined media and growing biosimilars market drives the segment growth
By type, the liquid media segment captured the highest revenue share of 62.9% in 2023. This is attributed to increasing number of biopharmaceutical manufacturers, both downstream and upstream, are switching from premixed powders to liquid media and hence, propelling market growth
By end-user, The pharmaceutical and biotechnology companies segment captured the highest revenue share of 34.25% in 2023, owing to the expansion of the current manufacturing capacities coupled with increasing prevalence of chronic disease which in turn demands for novel therapeutic drugs

Cell Culture Media Market Report Segmentation

Grand View Research has segmented the global cell culture media market on the basis of on product, application, type, end-use, and region:

Cell Culture Media Product Outlook (Revenue, USD Million, 2018 - 2030)

Serum-free Media
- CHO Media
- BHK Medium
- Vero Medium
- HEK 293 Media
- Other Serum-free media
Classical Media
Stem Cell Culture Media
Specialty Media
Chemically Defined Media
Other Cell Culture Media

Cell Culture Media Application Outlook (Revenue, USD Million, 2018 - 2030)

Biopharmaceutical Production
- Monoclonal Antibodies
- Vaccines Production
- Other Therapeutic Proteins
Diagnostics
Drug Screening And Development
Tissue Engineering And Regenerative Medicine
- Cell And Gene Therapy
- Other Tissue Engineering And Regenerative Medicine Applications
Other Applications

Cell Culture Media Type Outlook (Revenue, USD Million, 2018 - 2030)

Liquid Media
Semi-solid And Solid Media

Cell Culture Media End-use Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceutical And Biotechnology Companies
Hospitals And Diagnostic Laboratories
Research And Academic Institutes
Other End-users

Cell Culture Media Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America
- US
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Key Cell Culture Media Company Insights

Key players in cell culture media market are implementing various strategies including partnership, merger and acquisition, geographical expansion, and strategic collaboration to expand their market presence. In July 2023, Merck KGaA invested USD 24.38 million to boost cell culture media production in the U.S. This development expanded the production capacity of the Lenexa facility to manufacture cell culture media.
In September 2023, Celltrion invested USD 94.5 million to construct a facility with an annual production capacity of 8 million vials in Songdo, Incheon. The new development is expected to increase the bioreactor capacity to 600,000 L and will be operational in 2027. In March 2023, Samsung Biologics announced that it would commence the construction of a fifth plant holding a capacity of 180,000 liters. Post completion, Samsung Biologics will maintain its global biomanufacturing capacity leadership with a total of 784,000 liters.

Key Cell Culture Media Company Insights